

VI. Literaturverzeichnis

- 1 STATISTISCHES BUNDESAMT DER BUNDESREPUBLIK DEUTSCHLAND: Todesursachenstatistik 2002, www.destatis.de
 - 2 Gesundheitsbericht für Deutschland 1998: Akuter Myokardinfarkt. www.gbe-bund.de
 - 3 JESSUP M., BROZENA S.: Heart failure. *N. Engl. J. Med.* 2003; 348: 2007-2018
 - 4 JOHANN HALEN (STATISTISCHES BUNDESAMT DER BUNDESREPUBLIK DEUTSCHLAND): Pressekonferenz „Krankheitskosten in Deutschland im Jahr 2002“. www.destatis.de
 - 5 RIEDE N., SCHÄFER H.-E.: Allgemeine und spezielle Pathologie. Stuttgart 1995
 - 6 CLEUTJENS J. P. M., BLANKENSTEIJN W. M., DAEMEN M.J.A.P., SMITS J. F. M.: The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. *Cardiovasc. Res* 1999; 44: 232-241
 - 7 ZHANG J., YU Z.-X., HILBERT S. L., YAMAGUCHI M., CHADWICK D. P., HERMAN E. H., FERRANS V. J.: Cardiotoxicity of human recombinant interleukin-2 in rats. *Circulation* 1993; 87: 1340-1353
 - 8 MAJNO G., JORIS I.: Apoptosis, oncosis, and necrosis - an overview of cell death. *Am. J. Pathol.* 1995; 146: 3-1
 - 9 FRANGOIANNIS N. G., SMITH C. W., ENTMANN M. L.: The inflammatory response in myocardial infarction. *Cardiovasc. Res.* 2002; 53: 31-47
 - 10 SWYNGHEDAUW B.: Molecular mechanisms of myocardial remodeling. *Ann. Rev. Med.* 2001; 52: 15-27
 - 11 WEI S., CHOW L.T.C., SHUM I.O.L., QIN L., SANDERSON J.E.: Left and right ventricular collagen type I/III ratios and remodeling post-myocardial infarction. *J. Cardiac Fail.* 1999; 5: 117-126
 - 12 RAUCHHAUS M., MÜLLER-WERDAN U.: Zytokine bei Herzerkrankungen. *Internist* 2001; 42: 75-84
 - 13 LOPPNOW H.: Zytokine: Klassifikation, Rezeptoren, Wirkungsmechanismen. *Internist* 2001; 42: 13-27
 - 14 THOMSON A. (HRSG.): The cytokine handbook. London, Großbritannien, 1998
 - 15 AGGARWAL B. B., PURI R. K. (HRSG.): Human cytokines: their role in disease and therapy. Cambridge, USA, 1995
 - 16 WHO-IUIS NOMENCLATURE SUBCOMMITTEE ON INTERLEUKIN DESIGNATION. Nomenclature for secreted regulatory proteins of the immune system (interleukins). *Immunol. Today.* 1992; 13: 118
 - 17 AUKRUST P., UELAND T., LIEN E., BENDTZEN K., MÜLLER F., ANDREASSEN A. K., NORDØY I., AASS H., ESPEVIK T., SIMONSEN S., FRØLAND S. S., GULLESTAD L.: Cytokine network in congestive heart failure secondary to
-

- ischemic or idiopathic dilated cardiomyopathy. *Am. J. Cardiol.* 1999; 83: 376-382
- 18 RAUCHHAUS M., DOHNER W., FRANCIS D. P., DAVOS C., KEMP M., LIEBENTHAL C., NIEBAUER J., HOOPER J., VOLK H.-D., COATS A. J. S., ANKER S. A.: Plasma cytokine parameters and mortality in patients with chronic heart failure. *Circulation* 2000; 102: 3060-3067
 - 19 PETRETTA M., CONDORELLI G. L., SPINELLI L., SCOPACASA F., DE CATERINA M., LEOSCO D., VICARIO M. L. E., BONADUCE D.: Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure. *Am. Heart J.* 2000; 140: E28
 - 20 BLUM A., MILLER H.: Pathophysiological role of cytokines in congestive heart failure. *Ann. Rev. Med.* 2001; 52: 15-27
 - 21 ADAMOPOULOS S., PARISSIS J. T., KREMASTINOS D. T.: A glossary of circulating cytokines in chronic heart failure. *Europ. J. Heart Fail.* 2001; 3: 517-526
 - 22 TORRE-AMIONE G., KAPADIA S., LEE J., BIES R. D., LEBOVITZ R., MANN D. L.: Expression and functional significance of tumor necrosis factor receptors in human myocardium. *Circulation* 1995; 92: 1487-1493
 - 23 MATSUMORI: Cytokines in myocarditis and cardiomyopathies. *Curr. Opin. Cardiol.* 1996; 11: 302-309
 - 24 MARRIOTT J. B., GOLDMANN J. H., KEELING P. J., BAIG M. K., DALLEISH A. G., MCKENNA W. J.: Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives. *Heart* 1996; 75: 287-290
 - 25 NEUMANN F.-J., OTT I., GAWAZ M., RICHARDT G., HOLZAPFEL H., JOCHUM M., SCHÖMIG A.: Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. *Circulation* 1995; 92: 748-755
 - 26 MARX N., NEUMANN F.-J., OTT I., GAWAZ M., KOCH W., PINKAU T., SCHÖMIG A.: Induction of cytokine expression in leukocytes in acute myocardial infarction. *J. Am. Coll. Cardiol.* 1997; 30: 165-170
 - 27 HERSKOWITZ A., CHOI S., ANSARI A. A., WESSELINGH S.: Cytokine mRNA expression in posts ischemic/reperfused myocardium. *Am. J. Pathol.* 1995; 146: 419-428
 - 28 SHARMA R., COATS A. J. S., ANKER S. D.: The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. *Internat. J. Cardiol.* 2000; 72: 175-18
 - 29 STANGL V., BAUMANN G., STANGL K., FELIX S. B.: Negative inotropic mediators released from the heart after myocardial ischemia-reperfusion. *Cardiovasc. Res.* 2002; 53: 12-30
 - 30 VASAN R. S., SULLIVAN L. M., ROUBENOFF R., DINARELO C. A., HARRIS T., BENJAMIN E. J., SAWYER D. B., LEVY D., WILSON W. F., D'AGOSTINO R. B.: Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction. *Circulation* 2003; 107: 1486-1491
 - 31 KATZ S. D., RAO R., BERMAN J. W., SCHWARZ M., DEMOPOULOS L., BIJOU R., LEJEMTEL T. H.: Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. *Circulation* 1994; 90: 12-16
-

-
- 32 SETA Y, SHAN K., BOZKURT B., ORAL H., MANN D. M.: Basic mechanisms in heart failure: the cytokine hypothesis. *J. Cardiac Fail.* 1996; 2: 243-249
- 33 ANKER S. D., CLARK A. L., KEMP M., SALSURY C., TEIXEIRA M. M., HELLEWELL P. G., COATS A. J. S.: Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. *J. Am. Coll. Cardiol.* 1997; 30: 997-1001
- 34 DINARELLO C. A., POMERANTZ B. J.: Proinflammatory cytokines in heart disease. *Blood Purification* 2001; 19: 314-321
- 35 FINKEL M. S., ODDIS C. V., JACOB T. D., WATKIS S. C., HATTLER B. G., SIMMONS R. L.: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. *Science* 1992; 257: 387-389
- 36 CAIN B.S., MELDRUM D.R., DINARELLO C.A., MENG X., JOO K.S., BANERJEE A., HARKEN A.H.: Tumor necrosis factor- α and interleukin-1 β synergistically depress human myocardial function. *Crit. Care Med.* 1999; 27: 1309-1318
- 37 PAGANI F. D., BAKER L. S., HSI C., KNOX M., FINK M. P., VISNER M. S.: Left ventricular and diastolic dysfunction after infusion of tumor necrosis factor- α in conscious dogs. *J. Clin. Invest.* 1996; 97: 1204-1210
- 38 GIVERTZ M. M., COLUCCI W. S.: New targets for heart failure therapy: endothelin, inflammatory cytokines, and oxidative stress. *Lancet* 1998; 352(suppl I): 34-38
- 39 ENTMANN M. L., YOUKER K., SHAPPELL, SIEGEL C., ROTHLEIN R., DREYER W. J., SCHMALSTIEG F. C., SMITH C. W.: Neutrophil adherence to isolated adult canine myocyte. *J. Clin. Invest.* 1990; 85: 1497-1506
- 40 MORGAN D. A., RUSCETTI F. W., GALLO R.: Selective in vitro growth of t-lymphocytes from normal human bone marrows. *Science* 1976; 193: 1007-1008
- 41 AARDEN L. C., BRUNNER T. K., CEROTTINI J. C.: Revised nomenclature for antigen-nonspecific t-cell proliferation and helper factors. *J. Immunol.* 1979; 123: 2928-2929
- 42 TANIGUCHI T., MATSUI H., FUJITA T., TAKAOKA C., KASHIMA N., YOSHIMOTO R., HAMURO J.: Structure and expression of a cloned cDNA for human interleukin-2. *Nature* 1983; 302: 305-310
- 43 GILLIS S., FERM M. M., OU W., SMITH K. A.: T cell growth factor: parameters of production and a quantitative microassay for activity. *J. Immunol.* 1978; 120: 2027-32
- 44 TANIGUCHI T., MINAMI Y.: The IL-2/IL-2 receptor system: a current overview. *Cell* 1993; 73: 5-8
- 45 MCNAMARA J., KOMP D. M.: Interleukin-2: a major lymphokine. *J. Ped.* 1989; 114: 420-422
- 46 LÖFFLER G., PETRIDES P. E.: *Biochemie und Pathobiochemie.* Berlin / Heidelberg 1997
- 47 LIN J., WEISS A.: T-cell receptor signalling. *J. Cell Science* 2001; 114: 243-244
- 48 SMITH K. A.: Interleukin-2: inception, impact, and implications. *Science* 1988; 240: 1169-1176
-

-
- 49 JELINEK D. F., LIPSKY P. E.: Regulation of human B lymphocyte activation, proliferation, and differentiation, *Adv. Immunol.* 1987: 40: 1-59
- 50 ITOH K., INOUE T., ITO K., HIROHATA S.: The interplay of interleukin-10 (IL-10) and interleukin-2 (IL-2) in humoral immune response: IL-10 synergizes with IL-2 to enhance responses of human b-lymphocytes in a mechanism which is different from upregulation of CD25 expression. *Cell. Immunol.* 1994: 157: 478-488
- 51 WEIGENT D. A., BLALOCK J. E.: Associations between the neuroendocrine and immune systems. *J. Leukoc. Biol.* 1995: 57:137-150
- 52 YRON I., WOOD T. A., SPIESS P. J., ROSENBERG S. A.: In vitro growth of murine t-cells v. the isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. *J. Immun.* 1980: 125: 238-245
- 53 LOTZE M. T., CHANG A. E., SEIPP C. A., SIMPSON C., VETTO J. T., ROSENBERG S. A.: High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity, and histologic findings. *JAMA* 1986: 256: 3117-3124
- 54 MULÉ J. J., SHU S., ROSENBERG S. A.: The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 *in vivo*. *J. immunol.* 1985: 135: 646-652
- 55 LAFRENIERE R., ROSENBERG S. A.: Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin-2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. *J. Immunol.* 1985: 135: 4273-80
- 56 ROSENBERG S. A., LOTZE M. T., MUUL L. M., LEITMAN S., CHANG A. E., ETTINGHAUSEN S. E., MATORY Y. L., SKIBBER J. M., SHILONI E., VETTO J. T., SEIPP C. A., SIMPSON C., REICHERT C. M.: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. *N. Engl. J. Med.* 1985: 313: 1485-1492
- 57 ROSENBERG S. A., LOTZE M. T., MUUL L. M., CHANG A. E., AVIS F. P., LEITMAN S., LINEHAM W. M., ROBERTSON C.N., LEE R. E., RUBIN J. T., SEIPP C. A., SIMPSON C., WHITE D. E.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. *N. Engl. J. Med.* 1987: 316: 889-897
- 58 OGNIBENE F. P., ROSENBERG S. A., LOTZE M., SKIBBER J., PARKER M. M., SHELHAMMER J. H., PARRILLO J. E.: Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. *Chest* 1988: 94: 750-754
- 59 LEE R. E., LOTZE M. T., SKIBBER J. M., TUCKER E., BONOW R. O., OGNIBENE F. P., CARRASQUILLO J. A., SHELHAMMER J. H., PARRILLO J. E., ROSENBERG S. A.: Cardiorespiratory effects of immunotherapy with interleukin-2. *J. Clin. Oncol* 1989: 7: 7-20
- 60 FRAGASSO G., TRESOLDI M., BENTI R., VIDAL M., MARCATTI M., BORRI A., BESANA C., GERUNDINI P. P., RUGARLI C., CHIERCHIA S.: Impaired left ventricular filling rate induced by treatment with recombinant interleukin-2 for advanced cancer. *Br. Heart J.* 1994: 71: 166-169
-

-
- 61 BELLDEGRUN A., WEBB D. E., AUSTIN III H. A., STEINBERG S. M., WHITE D. E., LINEHAN W. M., ROSENBERG S. A.: Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. *Ann. Intern. Med.* 1987; 106: 817-822
- 62 LOTZE M. T., MATORY Y. L., RAYNER A. A., ETTINGHAUSEN S. E., VETTO J. T., SEIPP C. A., ROSENBERG S. A.: Clinical effects and toxicity of interleukin-2 in patients with cancer. *Cancer* 1986; 58: 2764-2772
- 63 WEST W. H., TAUER K. W., YNNANELLI R., MARSHALL G. D., ORR D. W., THURMAN G. B., OLDHAM R. K.: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. *N. Engl. J. Med.* 1987; 316: 898-905
- 64 ROSENSTEIN M., ETTINGHAUSEN S. E., ROSENBERG S. A.: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. *J. Immun.* 1986; 137(5): 1735-1742
- 65 MANN H., WARD J. H., SAMLOWSKI W. E.: Vascular leak syndrome associated with interleukin-2: chest radiographic manifestations. *Radiology* 1990; 176: 191-194
- 66 COTRAN R. S., POBER J. S., GIMBRONE M. A., SPRINGER T. A., WIEBKE E. A., GASPARI A. A., ROSENBERG S. A., LOTZE M. T.: Endothelial activation during interleukin-2 immunotherapy. *J. Immun.* 1987; 139: 1883-1888
- 67 FUJITA S., PURI R. K., YU Z.-X., TRAVIS W. D., FERRANS V. J.: An ultrastructural study of in vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin-2. *Cancer* 1991; 68: 2169-2174
- 68 SCHECHTER D., NAGLER A., ACKERSTEIN A., NASSAR H., ADMON D., NAPARSTEK E., REIN A. J. J. T.: Recombinant interleukin-2 and interferon- α immunotherapy following autologous bone marrow transplantation cardiovascular toxicity. *Cardiology* 1992; 80: 4168-171
- 69 KRAGEL A. H., TRAVIS W. D., STEIS R. G., ROSENBERG S. A., ROBERTS W. C.: Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer. *Cancer* 1990; 66: 1513-1516
- 70 BUZDAR A. U., KRAKOFF I. H., BURKETT M. G.: Acute cardiomyopathy as a consequence of treatment with interleukin-2 and interferon- α in a patient with metastatic carcinoma of the breast. *Am. J. Clin. Oncol.* 1991; 14: 530-533
- 71 ATKINS M. B., GOLLOB J. A., SOSMAN J. A., McDERMOTT D. F., TUTIN L., SOROKIN P., PARKER R. A., MIER J. W.: A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin-2, and IFN-alpha 2B in patients with metastatic melanoma. *Clin. Cancer Res.* 2002; 8: 3075-3081
- 72 KRUIT W. H., PUNT K. J., GOEY S. H., DE MULDER P. H., VAN HOOGENHUYZE D. C., HENZEN-LOGMANS S. C., STOTER G.: Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. *Cancer* 1994; 74: 2850-2856
- 73 OSANTO S., CLUITMANS F. H. M., FRANKS C. R., BOSKER H. A., CLETON F. J.: Myocardial injury after interleukin-2 therapy. *Lancet* 1988; 2: 48-49
-

-
- 74 MCGOWAN F. X., TAKEUCHI K., DEL NIDO P. J., DAVIS P. J., LANCASTER J. R., HATTLER B. G.: Myocardial effects of interleukin-2. *Transplantation Proceedings* 1994; 26: 209-210
- 75 WEISENSEE D., BEREITER-HAHN J., SCHOEPPE W., LÖW-FRIEDRICH I.: Effects of cytokines on the contractility of cultured cardiac myocytes. *Int. J. Immunopharmac.* 1993; 15: 581-587
- 76 HIBBS J.B., WESTENFELDER C., TAINTOR R., VAVRIN Z., KABLITZ C., BARANOWSKI R. L., WARD J. H., MENLOVE R. L., MCMURRY M. P., KUSHNER J. P., SAMLOWSKI W. E.: Evidence for cytokine-inducible nitric oxide synthesis from l-arginine in patients receiving interleukin-2 therapy. *J. Clin. Invest.* 1992; 89: 867-877
- 77 DE BRACCO M. M. E., FINK S. B., FINIASZ M., BORDA E. S., STERIN-BORDA L.: Positive inotropic effect of interleukin-2. Role of phospholipases and protein kinase C. *Int. J. Immunopharmac* 1991; 13: 509-515
- 78 DE BRACCO M. M. E., BORDA E. S., STERIN-BORDA L.: Opposite effects of interleukin-2 (IL-2) and interferon gamma (IFN- γ) on rat atria contractility. *Acta Physiologica, Pharmacologica et Therapeutika Latinoamericana* 1995; 45: 165-176
- 79 FINK S., FINIASZ M., STERIN-BORDA L., BORDA E., DE BRACCO M. M. E.: Interleukin 2 stimulates heart contractility in the presence of exogenous arachidonate or the calcium ionophore a23187. *Immunology Letters* 1988; 17: 183-188
- 80 FINK S. B., FINIASZ M., STERIN-BORDA L., BORDA E., DE BRACCO M. M. E.: Stimulation of heart contractility by supernatants from lectin-activated lymphocytes. Role of IL-2. *Int. J. Immunopharmac.* 1989; 11: 367-370
- 81 STERIN-BORDA L., LEIROS C. P., BORDA E. S., DE BRACCO M. M. E.: Effects of IL-2 on the myocardium. Participation of the sympathetic system. *J. Mol. Cell. Cardiol.* 1996; 28: 2457-2465
- 82 MAZZONE A., DE SERVI S., VEZZOLI M., FOSSATI G., MAZZUCHELLI I., GRITTI D., OTTINI E., MUSSINI A., SPECCHIA G.: Plasma levels of interleukin 2, 6, 10 and phenotypic characterization of circulating t-lymphocytes in ischemic heart disease. *Atherosclerosis* 1999; 145: 369-374
- 83 SIMON A. D., YAZDANI S., WANG W., SCHWARTZ A., RABBANI L. E.: Elevated plasma levels of interleukin-2 and soluble IL-2 receptor in ischemic heart disease. *Clin. Cardiol.* 2001; 24: 253-256
- 84 WU C. J., LOVETT M., WONG-LEE J., MOELLER F., KITAMURA M., GORALSKI T. J., BILLINGHAM M. E., STRANES V. A., CLAYBERGER C.: Cytokine gene expression in rejecting cardiac allografts. *Transplantation* 1992; 54: 326-332
- 85 CAFORIO A. L. P., GOLDMAN J. H., BAIG M. K., MAHON N. J., HAVEN A. J., SOUBERBIELLE B. E., HOLT D. W., DALGLEISH A. G., MCKENNA W. J.: Elevated serum levels of soluble interleukin-2 receptor, neopterin and β 2-microglobulin in idiopathic dilated cardiomyopathy: relation to disease severity and autoimmune pathogenesis. *Europ. J. Heart Fail.* 2001; 3: 155-163
- 86 ELAHI A. W., VIJAYAKUMAR A. N., LICHSTEIN E., MOKHTARIAN F.: Interplay of antibody and t-cell responses in acute myocardial infarction. *J. Lab. Clin. Med.* 2001; 138: 112-118
-

-
- 87 SUN Y., WEBER K. T.: Cardiac remodeling by fibrous tissue: role of local factors and circulating hormones. *Ann. Med.* 1998: 30 Suppl 1: 3-8
- 88 DHALLA N. S., KAURA D., LIU X., BEAMISH R. E.: Mechanisms of subcellular remodelling in post-infarct heart failure. *EXS* 1996: 76: 463-477
- 89 WEBER K. T., SUN Y., CLEUTJENS J. P.: Structural remodeling of the infarcted rat heart. *EXS* 1996: 76: 489-499
- 90 VÖLLER H., DIETZ R.: Linksventrikuläres Remodeling: Pathophysiologische Mechanismen und Therapieempfehlungen. *Z. Kardiol.* 1999: 88: 982-990
- 91 BARRY W. H.: Mechanisms of immune-mediated myocyte injury. *Circulation* 1994: 89: 2421-2432
- 92 MULLANE K.M., WESTLIN W., KRAEMER R.: Activated neutrophils release mediators that may contribute to myocardial injury and dysfunction associated with ischemia and reperfusion. *Ann. N. Y. Acad. Sci.* 1988: 524: 103-121
- 93 THE DIGITALIS INVESTIGATION GROUP: The effect of digoxin on mortality and morbidity in patients with heart failure. *N. Engl. J. Med.* 1997: 336: 525-533
- 94 THE CONSENSUS TRIAL STUDY GROUP: Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north scandinavian enalapril survival study (CONSENSUS). *N. Engl. J. Med.* 1987: 316:1429-1435
- 95 Studies of left ventricular dysfunction (SOLVD)--rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. *Am. J. Cardiol.* 1990: 66: 315-322
- 96 ISIS-4 (FOURTH INTERNATIONAL STUDY OF INFARCT SURVIVAL) COLLABORATIVE GROUP: ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. *Lancet* 1995: 345: 669-685
- 97 FORTH W. (HRSG.): Allgemeine und spezielle Pharmakologie und Toxikologie. Heidelberg 1996
- 98 PACKER M., FOWLER M. B., ROECKER E. B., COATS A. J., KATUS H. A., KRUM H., MOHACSI P., ROULEAU J. L., TENDERA M., STAIGER C., HOLCSLAW T. L., AMANN-ZALAN I., DEMETS D. L.; CARVEDILOL PROSPECTIVE RANDOMIZED CUMULATIVE SURVIVAL (COPERNICUS) STUDY GROUP: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. *Circulation* 2002: 106: 2194-2199
- 99 MERIT-HF STUDY GROUP: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). *Lancet* 1999: 353: 2001-2007
- 100 PAULUS W. J.: How are cytokines activated in heart failure? *Europ. J. Heart Fail.* 1999: 1: 309-312
- 101 TRAUNECKER A., SCHNEIDER J., KIEFER H., KARJALAINEN K.: Highly efficient neutralisation of HIV with recombinant CD4-immunoglobulin molecules. *Nature* 1989: 339: 68-70
-

-
- 102** CAPON D. J., CHAMOX S. M., MORDENTI J., MASTERS S. A., GREGORY A., MITSUYA H., BYRN R. A., LUCAS C., WURM M., GROOPMAN J. E., BRODER S., SNITH D. H.: Designing CD4 immunoadhesins for AIDS. *Nature* 1989; 337: 525-531
- 103** LANDOLFI N. F.: A chimeric IL-2/Ig molecule possesses the functional activity of both proteins. *J. Immun.* 1991; 146: 915-919
- 104** KUNZENDORF U., POHL T., BULFONE-PAUS S., KRAUSE H., NOTTER M., ONU A., WALZ G., DIAMANTSTEIN T. Suppression of cell-mediated and humoral immune responses by an interleukin-2-immunoglobulin fusion protein in mice. *J. Clin. Invest.* 1996; 97: 1204-1210
- 105** RÜCKERT R., HERZ U., PAUS R., UNGUREANU D., POHL T., RENZ H., BULFONE-PAUS S.: IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL-2-G2b fusion protein inhibits both. *Eur. J. Immunol.* 1998; 28:3312-3320
- 106** KUNZENDORF U., POHL T., BULFONE-PAUS S., KRAUSE H., ZIEGLER E., ONU A., DISTLER A.: Immunomodulation in experimental and clinical nephrology using chimeric proteins. *Kidney and Blood Res.* 1996; 19: 201-204
- 107** TSCHÖPE W., HERINGER-WALTHER S., HAUKE D., BADER M., SCHULTHEISS H.-P., WALTHER T.: Myocardial bradykinin B2-receptor expression at different time points after induction of myocardial infarction. *J. Hypertension* 2000; 18: 223-228
- 108** SPILLMANN F., ALTMANN C., SCHEELER M., BARBOSA M., WESTERMANN D., SCHULTHEISS H.-P., WALTHER T., TSCHÖPE C.: Regulation of cardiac bradykinin B1- and B2-receptor mRNA in experimental ischemic, diabetic, and pressure-overload-induced cardiomyopathy. *Int. J. Immunopharmac.* 2002; 2: 1823-1832
- 109** NOUTSIAS M., FECHNER H., DE JONGE H., WANG X., DEKKERS D., HOUTSMULLER A. B., PAUSCHINGER M., BERGELSON J., WARRAICH R., YACOUB M., HETZER R., LAMERS J., SCHULTHEISS H.-P., POLLER W.: Human coxsackie-adenovirus receptor is colocalized with integrins V3 and V5 on the cardiomyocyte sarcolemma and upregulated in dilated cardiomyopathy. *Circulation* 2001; 104: 275-280
- 110** PAUSCHINGER M., KNOPF D., PETSCHAUER S., DOERNER A., POLLER W., SCHWIMMBECK P. L., KÜHL U., SCHULTHEISS H.-P.: Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. *Circulation* 1999; 99: 2750-2756
- 111** NOUTSIAS M., PAUSCHINGER M., OSTERMANN K., ESCHER F., BLOHM J. H., SCHULTHEISS H.-P., KUHL U.: Digital image analysis system for the quantification of infiltrates and cell adhesion molecules in inflammatory cardiomyopathy. *Proinfla. Med. Sci. Monit.* 2002; 8: MT59-71
- 112** SOBOTKA P. A., McMANNIS J., FISHER R. I., STEIN D. G., THOMAS J. X. (JR.): Effects of interleukin-2 on cardiac function in the isolated rat heart. *J. Clin. Invest.* 1990; 86: 845-850
- 113** NEUBAUER S., HORN M., NAUMANN A., TIAN R., HU K., LASER M., FRIEDRICH J. GAUDRON P., SCHNACKERZ K., INGWALL J. S., ERTL G.: Impairment of energy metabolism in intact residual myocardium of rat hearts with chronic myocardial infarction. *J. Clin. Invest.* 1995; 95: 1092-1100
- 114** BUJA L. M.: Modulation of the myocardial response to ischemia. *Lab. Invest.* 1998; 78: 1345-1373
-

-
- 115 GUDBJARNASON S., RAVENS K. G., MATHES P.: Metabolic changes in infarcted and non-infarcted myocardium during the postinfarction period. *Recent. Adv. Stud. Cardiac. Struct. Metab.* 1972: 1: 439-46
- 116 ENTMANN M. L., YOUKER K., SHOJI T., KULKIELKA G., SHAPPELL S. B., TAYLOR A. A., SMITH C. W.: Neutrophil induced oxidative injury of cardiac myocytes. *J. Clin. Invest.* 1992: 90: 1335-1345
- 117 ENTMANN M. L., MICHAEL L., ROSSEN R. D., DREYER W. J., ANDERSON D. C., TAYLOR A. A., SMITH C. W.: Inflammation in the course of early myocardial ischemia. *FASEB J.* 1991: 5: 2529-2537
- 118 SCHWARTZENTRUBER D. J.: Guidelines for the safe administration of high-dose interleukin-2. *J. Immunotherapy* 2001: 24: 287-293
- 119 ANDREW J. A., MAYER B.: Enzymatic function of nitric oxide synthetases. *Cardiovasc. Res.* 1999: 43: 521-531
- 120 SHINDO T., IKEDA U., OHKAWA F., KAWAHARA Y., YOKOYAMA M., SHIMADA K.: Nitric oxide synthesis in cardiac myocytes and fibroblasts by inflammatory cytokines. *Cardiovasc. Res.* 1995: 29: 813-819
- 121 BALLIGAND J.-L., UNGUREANU D., KELLY R. A., KOBZIK L., PIMENTAL D., MICHEL T., SMITH T. W.: Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. *J. Clin. Invest.* 1993: 91: 2314-2319
- 122 CAO C.-M., XIA Q., CHEN Y.-Y., ZHANG X., SHEN Y.-L.: Opioid receptor-mediated effects of interleukin-2 on the $[Ca^{2+}]_i$ transient and contraction in isolated ventricular myocytes of the rat. *Eur. J. Physiol.* 2002: 443: 635-642
- 123 CAO C.-H., XIA Q., BRUCE I. C., ZHANG X., FU C., CHEN J.-Z.: Interleukin-2 increases activity of sarcoplasmic reticulum Ca^{2+} -ATPase, but decreases its sensitivity to calcium in rat cardiomyocytes. *J. P. E. T.* 2003: 306: 572-580
- 124 FAVALLI L., LANZA E., ROZZA A., GALIMBERTI M., VILLANI F.: Evaluation of the cardiovascular toxic effect of recombinant interleukin-2 in rats. *Anticancer Res.* 1990: 10: 1693-1698
- 125 REES R. C.: *The biology and clinical applications of interleukin-2.* Oxford, Großbritannien 1990
- 126 POBER J., COTRAN R. S.: What can be learned from the expression of endothelial adhesion molecules in tissues? *Lab. Invest.* 1991: 64: 301-5
- 127 SMITH C. W., ENTMANN M. L., LANE C. L., BEAUDET A. L., TY T. I., YOUKER K., HAWKINS H. K., ANDERSON D. C.: Adherence of neutrophils to canine cardiac myocytes in vitro is dependent on intracellular adhesion molecule-1. *J. Clin. Invest.* 1991: 88:1216-1223
- 128 MAISCH B.: Ventricular remodeling. *Cardiology* 1996: 87(suppl 1): 2-10
- 129 VALGIMIGLI, CURELLO S., CECONI C., AGNOLETTI L., COMINI L., BACHETTI T., MERLI E., FERRARI R.: Symposium: programmed cell death-clinical reality and therapeutic strategies. neurohormones, cytokines and programmed cell death in heart failure: a new paradigm for the remodeling heart. *Cardiovasc. Drugs and Therapy* 2001: 15: 529-537
-

- 130** THE ACUTE INFARCTION RAMIPRIL EFFICIACY (AIRE) STUDY INVESTIGATORS: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. *Lancet* 1993; 342: 821-828
- 131** PFEFFER M. A., BRAUNWALD E., MOYE L. A., BASTA L., BROWN E. J. J.R., CUDDY T. E., DAVIS B. R., GELTMAN E. M., GOLDMAN S., FLAKER G. C.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. *N. Engl. J. Med.* 1992; 327: 669-677
- 132** GISSI-3 STUDY GROUP: GISSI-3 study protocol on the effects of lisinopril, of nitrates, and of their association in patients with acute myocardial infarction. GISSI-3-Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. *Am. J. Cardiol.* 1992; 70: 62C-69C
- 133** ISIS-4 (FOURTH INTERNATIONAL STUDY OF INFARCT SURVIVAL) COLLABORATIVE GROUP: ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. *Lancet* 1995; 345: 669-685
- 134** SHARP P. E.: The laboratory rat. Boca Raton, USA 1998
- 135** ROBERTS R., DEMELLO V., SOBEL B. E.: Deleterious effects of methylprednisolone in patients with myocardial infarction. *Circulation* 1976, 53 (3, Supp.I): 204-206
- 136** DAMÁS J. K., GULLESTAD L., AUKRUST P.: Cytokines as new treatment targets in chronic heart failure. *Curr. Control. Trials Cardiovasc. Med.* 2001; 2: 271-277
- 137** HENRIKSEN P. A., NEWBY D. E.: Therapeutic inhibition of tumor necrosis factor- α in patients with heart failure: cooling an inflamed heart. *Heart* 2003; 89: 14-18
- 138** BOZKURT B., KRIBBS S. B., CLUBB F. J., MICHAEL L. H., DIDENKO V. V., HORNSBY P. J., SETA Y., ORAL H., SPINALE F. G., MANN D. L.: Pathophysiologically relevant concentrations of tumor necrosis factor- α promote progressive left ventricular dysfunction and remodeling in rats. *Circulation* 1998; 97: 1382-1391
- 139** DESWAL A., BOZKURT B., SETA Y., PARILTI-EISWIRTH S., HAYES A., BLOSCH C., MANN D. L.: Safety and efficacy of a soluble p75 tumor necrosis factor receptor (enbrel, etanercept) in patients with advanced heart failure. *Circulation* 1999; 99: 3224-3226
- 140** ADU D., COCKWELL P., IVES N. J., SHAW J., WHEATLEY K.: Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. *BMJ* 2003; 326: 789-793
- 141** BROWN J. M., WHITE C. W., TERADA L. S., GROSSO M. A., SHANLEY P. F., MULVIN D. W., BANERJEE A., WHITMAN G. J. R., HARKEN A. H., REPINE J. E.: Interleukin-1 pretreatment decreases ischemia/reperfusion injury. *Proc. Natl. Acad. Sci. USA* 1990; 87: 5026-5030
- 142** GALLUCCI R. M., SIMEONOVA P. P., MATHESON J. M., KOMMINENI C., GURIEL J. L., SUGARAWA T., LUSTER M. I.: Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice. *FASEB J.* 2000; 14, 2525-2531
-

- 143** NAKANO M., KNOWLTON A. A., DIBBS Z., MANN D. L. : Tumor necrosis factor- α confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. *Circulation* 1998; 97: 1392-1400
- 144** BROWN J. M., ANDERSON B. O., REPINE J. E., SHANLEY P. F., WHITE C. W., GROSSO M. A., BANERJEE A., BENSARD D. D., HARKEN A. H.: Neutrophils contribute to TNF induced myocardial tolerance to ischemia. *J. Mol. Cell. Cardiol.* 1992; 24: 485-495
- 145** KURRELMEYER K. M., MICHAEL L. H., BAUMGARTEN G., TAFFET G. E., PESCHON J. J., SIVASUBRAMANIAN N., ENTMAN M. L., MANN D. L.: Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. *Proc. Natl. Acad. Sci. USA* 2000; 97: 5456-5461
- 146** TORRE-AMIONE G., KAPADIA S., BENEDICT C., ORAL H., YOUNG J. B., MANN D. L.: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). *J. Am. Coll. Cardiol.* 1996; 27: 1201-1206
- 147** MASCHKE T.: Business Publishing mit RagTime 5.5, Heidelberg 2001
- 148** HILDEBRANDT H. (HRSG.): Pschyrembel Medizinisches Wörterbuch. Berlin 1993
- 149** CHOUAIB S., FRADELIZI D.: The mechanism of inhibition of human IL-2 production. *J. Immun.* 1982; 129: 2463-2468
- 150** TORRE-AMIONE G., KAPADIA S., LEE J. BIES R. D., LEBOVITZ R., MANN D. L.: Resident cardiac mast cells degranulate and release preformed TNF- α , initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. *Circulation* 1998; 7: 699-710
- 151** NABATA T., FUKUO K., MORIMOTO S., KITANO S., MOMOSE N., HIROTANI A., NAKAHASHI T., NISHIBE A., HATA S., NIINOBU T., SUHARA T., SHIMIZU M., OHKUMA H., SAKURAI S., NISHIMAKI H., OGIHARA T.: Interleukin-2 modulates the responsiveness to angiotensin II in cultured vascular smooth muscle cells. *Atherosclerosis* 1997; 133: 23-30
- 152** PFEFFER M. A., McMURRAY J., LEIZOROVICZ A., MAGGIONI A. P., ROULEAU J.-L., VAN DE WERF F., HENIS M., NEUHART E., GALLO P., EDWARDS S., SELLERS M.A., VELAZQUEZ E., CALIFF R. : Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design. *Am. Heart J.* 2000; 140: 727-734
- 153** PITT B., WILLIAMS G., REMME W., MARTINEZ F., LOPEZ-SENDON J., ZANNAD F., NEATON J., RONIKER B., HURLEY S., BURNS D., BITTMAN R., KLEIMAN J.: The EPHEsus trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. *Cardiovasc. Drugs Ther.* 2001; 15: 79-87
- 154** CIBIS-II INVESTIGATORS AND COMMITTEES: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 1999; 353: 9-13
-